Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature
{{output}}
Objective/aim: SB4 (Benepali®), the Etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel®. In 2016, the Rheumatology Department at Blackpool Teaching Hospitals switched the Etan... ...
